U.S. Markets open in 4 hrs 48 mins

JNJ’s Infectious Diseases Segment Witnessed ~11% YoY Growth

Daniel Collins
JNJ’s Infectious Diseases Segment Witnessed ~11% YoY Growth

In the first quarter, Johnson & Johnson’s (JNJ) Infectious Diseases segment generated revenues of $830.0 million compared to $749.0 million in the first quarter of 2017, which reflected ~10.8% YoY (year-over-year) growth.